An Open Label, Multicenter, Extension Study to Evaluate the Long-term Safety of QGE031 240 mg s.c. Given Every 4 Weeks for 52 Weeks in Chronic Spontaneous Urticaria Patients Who Completed Study CQGE031C2201

Trial Profile

An Open Label, Multicenter, Extension Study to Evaluate the Long-term Safety of QGE031 240 mg s.c. Given Every 4 Weeks for 52 Weeks in Chronic Spontaneous Urticaria Patients Who Completed Study CQGE031C2201

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Ligelizumab (Primary)
  • Indications Urticaria
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 21 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Aug 2017 Planned End Date changed from 1 May 2019 to 13 Jun 2019.
    • 02 Aug 2017 Planned primary completion date changed from 1 May 2019 to 13 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top